JPRN-jRCT2031220512招募中3 期
RGB-19 Phase III Clinical Study
Watanabe Manabu0 个研究点目标入组 358 人开始时间: 2022年12月15日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 358
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Male or Female patients from 20 years to 75 years of age (both inclusive) when signing Informed Consent.
- •Active RA patients.
- •Patients who have an inadequate response to MTX.
排除标准
- •Patients who have received treatment with two or more biological DMARDs/their biosimilar products.
- •Patients who have ever received tocilizumab, any other IL-6 inhibitors or IL-6 receptor inhibitors, or Janus kinase inhibitors in the past.
- •Patients who are pregnant or possibly pregnant and/or breast-feeding, or patients planning to become pregnant during the study period.
研究者
相似试验
招募中
1 期
RGB-19 Phase I Clinical StudyHealthy ParticipantsJPRN-jRCT2031230029Watanabe Manabu110
已完成
3 期
A Phase 3b Clinical Study To Assess Whether Regular Administration Of Advate In The Absence Of Immunological Danger Signals Reduces The Incidence Rate Of Inhibitors In Previously Untreated Patients With Hemophilia ACoagulation Factor VIII deficiency / Blood disease10018849NL-OMON35535Baxter6
进行中（未招募）
不适用
Clinical study to find out whether regular infusions of ADVATE in the absence of immunological danger signals (eg. tissue damage/viral or bacterial infections) reduces the possibility of inhibitor in PUPs with hemophilia AEUCTR2011-000410-18-PLBaxter Innovations GmbH100
未知
3 期
Phase 3 Clinical Trial with MD-0901JPRN-jRCT2080222425MOCHIDA PHARMACEUTICAL CO., LTD.250
尚未招募
3 期
A study researching the effect of upfront cytoreductive surgery with or without intraperitoneal lavage under heated conditions (HIPEC) in subjects with stage III ovarian cancer - OVHIPEC-2CTRI/2023/08/056165Antoni Van Leeuwenhoek Netherlands Cancer Institute